Affiliations: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy | Department of Experimental Pathology, University of Bologna and Center for Applied Biomedical Research, Bologna, Italy | Department of Medical Oncology, Morgagni-Pierantoni Hospital, Forlì, Italy
Note: [] These authors contributed equally to this work.
Note: [] Corresponding author: Massimiliano Bonafe, M.D., Department of Experimental Pathology, University of Bologna, Bologna, Via San Giacomo 12, 40126 Bologna, Italy. Tel.: +39 051 6364009; Fax: +39 051 6363902; E-mail: [email protected]
Abstract: Background: Melanoma remains largely resistant to currently available chemotherapy, and new strategies have been proposed to flank standardized therapeutic protocols in an effort to improve efficacy. Such an approach requires good knowledge of the mechanisms involved in the resistance and survival of melanoma cells. In this context, the SLUG gene has recently been characterized as a major regulator of melanocytes and melanoma cell survival. Methods: We tested the hypothesis that an oligonucleotide-based short interfering RNA (siRNA) directed against the SLUG gene increases the susceptibility of melanoma cells to drugs such as cisplatin and fotemustine, which are frequently used to treat this cancer. Results: It was found that SLUG siRNA increased cisplatin-induced cell death and rendered the drug active in vitro at half its plasmatic peak concentration. Such activity was correlated with an upregulation of the pro-apoptotic gene, PUMA. Furthermore, SLUG siRNA increased the capacity of fotemustine to elicit cell death and induced p21WAF1 upregulation, resulting in cell cycle arrest. Interestingly, this pathway did not require functional p53. Conclusion: These findings suggest that SLUG siRNA enhances the efficacy of two of the most widely used drugs to treat melanoma.
Keywords: Slug gene, melanoma, short interfering RNA, cisplatin, fotemustine
